Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related death. It is estimated that over 800 thousand cases of liver cancer are diagnosed worldwide (more than 400 thousand cases in China) every year with a continuous increase in incidence. In 2012, around 746 thousand people died of liver cancer, including 383 thousand deaths in China. As the most effective targeted drug for liver cancer, Sorafenib brings hope to numerous tumor patients.
According to the report, Sorafenib has been growing since it entered China. In 2017, its sales value in China was about CNY 195 million. Currently, Sorafenib legally sold in China are all Bayer's products.
Cancer incidence continues to rise in China because of aggravating environmental pollution and changing lifestyle. Therefore, there will be a great demand for Sorafenib. After several links of circulation, Bayer's Sorafenib is so high-priced that many low-income patients cannot afford it. Some patients choose to purchase Sorafenib produced by Indian enterprises such as NATCO and smuggled to China because the price is only 2%-3% of that of Bayer's Sorafenib. Some Chinese enterprises have also started the development of generic drugs.
It is possible that China-made Sorafenib will appear on the market after 2022.
- Sales of Sorafenib in China
- Prices of Sorafenib in China
- Sales of Sorafenib in China by region
- Sales of India-made Sorafenib in China
- Prospects of Chinese Sorafenib market
Table of Contents
1.2 Development History of Sorafenib in China
1.3 Registration Information of Sorafenib in China
2.1.1 Sales Value
2.1.2 Sales Volume
2.2 Sales of Sorafenib in China by Region
2.2.1 Sales Value by Region
2.2.2 Sales Volume by Region
2.3 Sales of Sorafenib by Dosage Form
3.2 Indian Enterprises
3.3 Progress of China-made Generic Drugs
4.2 Generic Drugs Smuggled from India
5.2 Forecast on Competition Pattern
Chart Sales Value of Sorafenib Legally Sold in China, 2013-2017
Chart Sales Value of Sorafenib in Parts of China, 2013-2017
Chart Sales Volume of Sorafenib in China, 2013- 2017
Chart Sales Volume of Sorafenib in Parts of China, 2013-2017
Chart Market Share of Sorafenib Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Sorafenib Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value and Market Share of Sorafenib Tablets in China, 2013-2017
Chart Sales Volume and Market Share of Sorafenib Tablets in China, 2013-2017
Chart Prices of Bayer's Sorafenib in Several Chinese Cities, 2017-2018
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.